DE60334382D1 - Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen - Google Patents

Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen

Info

Publication number
DE60334382D1
DE60334382D1 DE60334382T DE60334382T DE60334382D1 DE 60334382 D1 DE60334382 D1 DE 60334382D1 DE 60334382 T DE60334382 T DE 60334382T DE 60334382 T DE60334382 T DE 60334382T DE 60334382 D1 DE60334382 D1 DE 60334382D1
Authority
DE
Germany
Prior art keywords
cell lysates
tumor cell
induced tumor
lysate
producing temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60334382T
Other languages
English (en)
Inventor
Steffen Goletz
Hans Baumeister
Ute Schoeber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycotope GmbH
Original Assignee
Glycotope GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope GmbH filed Critical Glycotope GmbH
Application granted granted Critical
Publication of DE60334382D1 publication Critical patent/DE60334382D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
DE60334382T 2002-08-16 2003-08-18 Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen Expired - Lifetime DE60334382D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02018512 2002-08-16
PCT/EP2003/009140 WO2004018659A1 (en) 2002-08-16 2003-08-18 Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds

Publications (1)

Publication Number Publication Date
DE60334382D1 true DE60334382D1 (de) 2010-11-11

Family

ID=31896837

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60334382T Expired - Lifetime DE60334382D1 (de) 2002-08-16 2003-08-18 Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen

Country Status (9)

Country Link
US (1) US7595192B2 (de)
EP (1) EP1530628B1 (de)
AT (1) ATE482720T1 (de)
AU (1) AU2003260426A1 (de)
DE (1) DE60334382D1 (de)
DK (1) DK1530628T3 (de)
ES (1) ES2353753T3 (de)
SI (1) SI1530628T1 (de)
WO (1) WO2004018659A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1530628T1 (sl) 2002-08-16 2011-02-28 Glycotope Gmbh Postopek za proizvodnjo s temperaturo induciranih lizatov tumorskih celic za uporabo kot imunogenske spojine
US8017388B2 (en) 2003-08-18 2011-09-13 Glycotope Gmbh Tumour cell lines and uses thereof
CA2557725C (en) * 2004-02-13 2015-06-30 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
JP5623004B2 (ja) * 2004-10-25 2014-11-12 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 熱ショックをかけたメラノーマ細胞体が装填された樹状細胞
WO2007001200A1 (fr) * 2005-06-23 2007-01-04 Obschestvo S Ogranichennoi Otvetsvennostyu 'rusgen' Cellules dendritiques matures chargees d'un polylysat de tumeurs, et vaccin antitumoral a base desdites cellules
GB0601598D0 (en) 2006-01-26 2006-03-08 Stathopoulos Apostolos Method
BRPI0716997B8 (pt) 2006-09-10 2021-05-25 Glycotope Gmbh proteína ou composição de moléculas de proteína, métodos para produção e uso da mesma
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
CL2007002825A1 (es) 2007-09-28 2008-05-30 Univ De Chile Oncobiomed Metodo para generar vacunas que estimulen el sistema inmune que comprende inducir celulas mononucleares de sangre periferica a que se diferencien a apc, para luego, separar dichas apc y mezclarlas con adyuvantes; extracto de celulas tumorales; y comp
EP2281844A1 (de) 2009-07-31 2011-02-09 Glycotope GmbH MUC-1-Antikörper
CA2844543A1 (en) 2011-08-22 2013-02-28 Glycotope Gmbh Microorganisms carrying a tumor antigen
CN109876137A (zh) * 2012-11-15 2019-06-14 厦门鹭佳生物科技有限公司 一种自体肿瘤疫苗的制备方法及其应用
WO2014102220A1 (en) * 2012-12-28 2014-07-03 Amphera B.V. Method for preparing an immunogenic lysate, the lysate obtained, dendritic cells loaded with such lysate and a pharmaceutical composition comprising the lysate or the dendritic cells
CN117815404A (zh) 2018-05-18 2024-04-05 第一三共株式会社 抗-muc1抗体-药物缀合物
CN114466666A (zh) * 2019-07-22 2022-05-10 托德·阿拉明 细胞治疗和治疗性回输方法
WO2024026505A2 (en) * 2022-07-29 2024-02-01 Amit Patel Disruption of telocyte activity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931275A (en) * 1985-12-02 1990-06-05 Yeda Research & Development Co., Ltd. Anti-tumor vaccines and their preparation
ATE301201T1 (de) 1993-06-07 2005-08-15 Vical Inc Für die gentherapie verwendbare plasmide
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
EP0906444A1 (de) 1996-04-19 1999-04-07 Gabriele Pecher Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
JP2003510334A (ja) * 1999-09-30 2003-03-18 コリクサ コーポレイション 癌及び感染症の予防及び治療のためのストレスタンパク質組成物及び方法
DE10139428A1 (de) 2001-08-17 2003-03-27 Nemod Immuntherapie Ag Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika
SI1529060T1 (sl) 2002-07-22 2015-01-30 Glycotope Gmbh Postopek za proizvodnjo imunostimulacijskih mucinov (MUCI)
SI1530628T1 (sl) 2002-08-16 2011-02-28 Glycotope Gmbh Postopek za proizvodnjo s temperaturo induciranih lizatov tumorskih celic za uporabo kot imunogenske spojine
US8017388B2 (en) * 2003-08-18 2011-09-13 Glycotope Gmbh Tumour cell lines and uses thereof

Also Published As

Publication number Publication date
DK1530628T3 (da) 2011-01-10
US20060127419A1 (en) 2006-06-15
ES2353753T3 (es) 2011-03-04
US7595192B2 (en) 2009-09-29
AU2003260426A1 (en) 2004-03-11
EP1530628A1 (de) 2005-05-18
EP1530628B1 (de) 2010-09-29
WO2004018659A1 (en) 2004-03-04
SI1530628T1 (sl) 2011-02-28
ATE482720T1 (de) 2010-10-15

Similar Documents

Publication Publication Date Title
DE60334382D1 (de) Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen
IL208795A0 (en) Multispecific deimmunized cd3-binders
WO2021064137A3 (en) Multi-specific binding proteins for cancer treatment
BR112013000822A2 (pt) método e método de duas etapas para a produção de uma população de células exterminadoras naturais (nk) ativadas, população de células nk ativadas e método para suprimir a proliferação de células tumorais
ATE407138T1 (de) Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
WO2019224025A3 (en) Antagonizing cd73 antibody
BR112015023036A2 (pt) método para preparar um produto alcaloide benzilisoquinolina e célula microbiana engenheirada que produz um produto alcaloide benzilisoquinolina
SG146682A1 (en) Modulation of eif4e expression
TW200716671A (en) Improved nanobodies against tumor necrosis factor-alpha
BR0210599A (pt) Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
NZ619576A (en) Compositions and methods for the treatment of infections and tumors
PH12021551241A1 (en) Expansion of natural killer cells and ilc3 cells with novel aromatic compounds
BRPI0610968A2 (pt) composição de sangue de cordão umbilical, e, métodos para tratar uma doença maligna ou distúrbio benigno associado com o sistema hemoatopoiético e para preparar uma composição de sangue umbilical
MXPA03010523A (es) Anticuerpos especificos para cd44v6.
RU2013111675A (ru) Рекомбинантный fc-гибридный белок пятого домена фибронектина типа iii dcc
WO2009062260A8 (en) Therapy for multiple sclerosis
ATE403005T1 (de) Rekombinantes mva und verfahren zur erzeugung davon
BRPI0410655A (pt) composição farmacêutica, método de tratar ou prevenir uma infecção pelo vìrus da raiva em um indivìduo em necessidade deste tratamento, vetor de expressão de rhabdovìrus recombinante, célula hospedeira de mamìfero, método de produzir uma anticorpo recombinante humano neutralizante do vìrus da raiva em uma célula de mamìfero, e, uso de uma combinação
ATE457349T1 (de) Granzyme b als ein hsp70/hsp70 peptid-abhängige apoptoseauslöser in tumorzellen
ATE491448T1 (de) Verfahren zur herstellung eines krebsimpfstoffs
WO2003090778A3 (en) Dna vaccine combined with an inducer of tumor cell apoptosis
WO2024083925A3 (en) Novel anti-napi2b antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof
WO2013040547A3 (en) Compounds and methods of immunization with tumor antigens
MX2023013078A (es) Anticuerpos de inmunorreceptor de celulas t con dominios ig e itim (anti-tigit), anticuerpos de cumulo de diferenciacion 96 (anti-cd96) y metodos de uso de estos.
DK1565196T3 (da) Fremgangsmåde til fremstilling af dendritceller til cancerterapi